Purpose: To test the efficacy of triple-refocusing MR spectroscopy (MRS) for improved detection of 2-hydroxyglutarate (2HG) in brain tumors at 3T in vivo. Methods: The triple-refocusing sequence parameters were tailored at 3T, with density-matrix simulations and phantom validation, for enhancing the 2HG 2.25-ppm signal selectivity with respect to the adjacent resonances of glutamate (Glu), glutamine (Gln), and gamma-aminobutyric acid (GABA). In vivo MRS data were acquired from 15 glioma patients and analyzed with LCModel using calculated basis spectra. Metabolites were quantified with reference to water. Results: A triple-refocusing sequence (echo time ¼ 137 ms) was obtained for 2HG detection. The 2HG 2.25-ppm signal was large and narrow while the Glu and Gln signals between 2.2 and 2.3 ppm were minimal. The optimized triple refocusing offered improved separation of 2HG from Glu, Gln and GABA when compared with published MRS methods. 2HG was detected in all 15 patients, the estimated 2HG concentrations ranging from 2.4 to 15.0 mM, with Cramer-Rao lower bounds of 2%-11%. The 2HG estimates did not show significant correlation with total choline. Conclusion: The optimized triple refocusing provides excellent 2HG signal discrimination from adjacent resonances and may confer reliable in vivo measurement of 2HG at relatively low concentrations. Magn Reson Med 78:40-48,
INTRODUCTION
Cancers reprogram their metabolism to meet the needs of rapid cell growth (1, 2) , resulting in alterations in metabolic profiles. The metabolic activity of tumors is predictive of their genotype and may also predict tumor grade and patient outcomes. The majority of World Health Organization grade 2 and grade 3 gliomas and secondary glioblastomas contain mutations in the metabolic enzymes isocitrate dehydrogenase (IDH) 1 and 2, and the mutations are associated with 2 to 3 times longer patient survival compared with IDH wild-type tumors (3) (4) (5) . These heterozygous mutations are confined to the active site of the enzyme and result in a neomorphic activity that causes the mutant enzyme to produce an oncometabolite, 2-hydroxyglutarate (2HG), and as a result 2HG, which is normally present in vanishingly small quantities, is elevated by 2 to 3 orders of magnitude in IDH-mutated gliomas (6) (7) (8) . Noninvasive identification of elevated 2HG therefore has significant clinical use in patient care.
In vivo detection of 2HG in patients by 1 H MR spectroscopy (MRS) at the widely available field strength 3T was recently reported by several researchers. Among the five nonexchangeable, J-coupled proton resonances of 2HG, the C4 proton resonances at approximately 2.25 ppm, which are proximate to each other, give rise to a large signal in most experimental situations and may be well detectable using short echo time (TE) point-resolved spectroscopy (PRESS) (9, 10) and optimized long TE PRESS (10) (11) (12) when the 2HG concentration is relatively high. The C2 proton resonance at 4.02 ppm, which is weakly coupled to the C3 proton spins, can be detected using Jdifference editing (11, 13, 14) , but the small edited signal from a single proton spin is difficult to assess reliably when the baseline at approximately 4 ppm is distorted due to the presence of artifactual signals arising from potential subject motion and/or imperfect cancelation of adjacent resonances, including water. Two-dimensional correlation spectroscopy provides excellent signal separation (13) , but the sensitivity is low compared with the aforementioned approaches, its applicability likely being limited to cases with high 2HG concentration.
At present, precise evaluation of 2HG at relatively low concentration with abundant signals in the proximity remains challenging at 3T. When targeting the 2HG 2.25-ppm resonance, the major interferences include glutamate (Glu) and glutamine (Gln). The Glu C4 proton and Gln C3 proton resonances (2.35 and 2.12 ppm, respectively) can interfere with 2HG estimation extensively when their signals are large compared with 2HG signal. The 2HG and interference resonances are all strongly coupled; consequently, the coherences evolve with time in complex manners. For example, the 2HG C4 proton signal is not symmetric with respect to the PRESS subecho times, TE 1 and TE 2 (11) . This complicated dependence of strongly coupled resonances on the inter-radiofrequency (RF) pulse timings can be used for manipulating the J-coupled spin coherences for detection of signals of interest. Triple refocusing (90 -180 -180 -180 ) has three subecho times and may provide a means of manipulating the J-coupled spin signals more effectively.
We propose a triple-refocusing sequence for 2HG measurement in which the subecho times and RF pulse duration are tailored, with numerical simulation and phantom validation, for generating a large and narrow 2HG signal at 2.25 ppm and suppressing the Glu, Gln, and gamma-aminobutyric acid (GABA) signals between 2.2 and 2.3 ppm. Preliminary in vivo data from 15 patients are presented.
METHODS
Fourteen patients with biopsy-confirmed IDH mutant gliomas and a patient with a lesion in the brainstem (men, n ¼ 6; women, n ¼ 9; age range, 25-67 y [median, 44 y]) were recruited for the present study. The IDH mutations were all IDH1 R132H according to immunohistochemical analysis of tumor tissue. The tumor locations were as follows: frontal, n ¼ 6; parietal, n ¼ 5; temporal, n ¼ 3; and brainstem, n ¼ 1. The protocol was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Written informed consent was obtained from patients prior to the scans.
Density-matrix simulation of three-dimensional volume localized triple refocusing was performed to optimize the sequence parameters for detection of the 2HG 2.25-ppm resonance. The time evolution of the density operator was calculated by solving the Liouville-von Neumann equation for the Hamiltonian that included Zeeman, chemical shift, and scalar coupling terms and shaped RF and gradient pulses using a product operator-based transformation matrix algorithm described in a prior study (11) . The spatial resolution of slice selection was set to 1%, namely, 0.01 ¼ sample length/number of pixels/slice thickness, where the sample length was two-fold greater than the slice thicknesses with number of pixels (isochromats) of 200. The MRS sequence had three 180 RF pulses following a 90 excitation RF pulse, as shown in Figure 1 . The 90 pulse and the first and third 180 pulses were slice selective, whereas the second 180 was non-slice selective. Volume localization RF pulses included a 9.8-ms long 90 pulse with bandwidth (at half amplitude) of 4.2 kHz and two 13.2-ms long 180 pulses with bandwidth of 1.3 kHz, at an RF field strength (B 1 ) of 13.5 mT, whose envelopes are shown in prior papers (10, 15) . Spectra of 2HG, GABA, Glu, and Gln were numerically calculated for various durations of the second 180 RF pulse and various subecho time sets (TE 1 , TE 2 , TE 3 ). The carrier frequencies of the RF pulses were all set to 2.5 ppm in the simulations. Published chemical shift and J-coupling constants were used for the simulations (16) (17) (18) . The computer simulation was programmed with MATLAB (MathWorks, Natick, Massachusetts, USA).
MR experiments were performed on a whole-body 3T scanner (Philips Medical Systems, Best, The Netherlands), equipped with a whole-body coil for RF transmission and an eight-channel phased-array head coil for reception. An in vitro test of the 2HG-optimized triple-refocusing sequence was conducted on a phantom solution with 2HG (8 mM) and glycine (Gly; 10 mM) at pH ¼ 7.0 and a temperature of 37 C. Data were acquired, with repetition time (TR) ¼ 9 s and TE ¼ 137 ms, from a 2 Â 2 Â 2 cm 3 voxel at the center of the phantom sphere (6 cm diameter). Phantom T 2 values of 2HG and Gly were evaluated from comparison of experimental and calculated spectra at 10 equidistant TEs between 50 and 500 ms. In vivo triple-refocused spectra were obtained from tumors identified by T 2 -weighted fluid-attenuated inversion recovery (T 2 -FLAIR) imaging. The MRS voxel size was 4-10 mL, depending on the tumor volume. MRS acquisition parameters included TR ¼ 2 s, sweep width ¼ 2.5 kHz, number of sampling points ¼ 2048, and number of signal averages (NSA) ¼ 128-512. Water suppression was obtained with a vendor-supplied four-pulse variable flip angle subsequence. First-and second-order shimming was performed using the fast automatic shimming technique by mapping along projections (FASTMAP) (19) . Up to 256-step RF phase cycling schemes, which had 4 orthogonal phases for each of the four RF pulses, were used to minimize potential outer-volume signals due to the presence of non-selective 180 RF pulse in the sequence. In addition, unsuppressed water was acquired from the voxel for eddy current compensation and multichannel combination. Unsuppressed water was also obtained with short-TE (13 ms) STEAM and TR ¼ 20 s for use as a reference in metabolite quantification. The RF carrier frequencies of the triple-refocusing sequence were set at 2.5 ppm and were adjusted for B 0 drifts in each excitation using a vendorsupplied tool (frequency stabilization). Surgical cavities, areas of intratumoral hemorrhage, cystic changes, and necrosis, identified on T 2 -FLAIR anatomical images, were excluded from the tumor voxels.
Spectral fitting was performed with LCModel software (20) , following apodization using a 1-Hz exponential function. The basis set for the fitting had in-house calculated model spectra of 21 metabolites, which included 2HG, Glu, Gln, GABA, N-acetylaspartate (NAA), creatine þ phosphocreatine (tCr), Gly, myo-inositol (mI), lactate (Lac), glutathione, alanine, acetate, aspartate, ethanolamine, phosphorylethanolamine, scyllo-inositol, taurine, N-acetylaspartylglutamate, glucose, succinate, and glycerophosphorylcholine þ phosphorylcholine (tCho). The spectral fitting was conducted between 0.5 and 4.1 ppm. Cram er-Rao lower bounds (CRLB), returned as the percentage standard deviation by LCModel, were used to determine the precision of the metabolite estimates. Metabolite concentrations were estimated with reference to water at 48 M for all tumors. Relaxation effects on metabolite signals were corrected using published metabolite T 2 and T 1 values and Equation [1] of Choi et al. (10); T 2 ¼ 170, 290, and 260 ms for tCr, tCho, and tNAA, respectively, and 180 ms for 2HG and other metabolites (21, 22) ; T 1 ¼ 1.2 s for 2HG, Glu, Gln, and mI, and 1.5 s for other metabolites (23, 24) . Data are presented as mean 6 standard deviation.
RESULTS
Triple-refocused spectra of 2HG were numerically calculated for 10 values of the nonselective, second 180 RF pulse duration (i.e., T NS180 p ¼ 14-32 ms with 2-ms increments) and for all possible combinations of subecho times TE 1 , TE 2 , and TE 3 (2-ms increments for each) for total TE between the shortest possible TE and 150 ms (total, $130,000 spectra). The result indicated that the 2HG 2.25-ppm peak amplitude overall increases with TE in a sinusoidal fashion, with temporal maxima at TEs of $78, $110, and $136 ms (Fig. 2) were preferable for minimizing the interferences from GABA, Glu, and Gln (Fig. 3) . To refine the T NS180 p and the subecho times, spectra of 2HG, GABA, Glu, and Gln were calculated for the aforementioned subecho time ranges, with 1-ms increments of subecho times and for T Figure 4a shows the spectra of 2HG, GABA, Glu, and Gln, calculated for the 2HG-optimized triple-refocusing sequence. For equal concentrations, the spectral range between 2.2 and 2.3 ppm was dominated by the 2HG and GABA signals, with minimal contributions from Glu and Gln. The Glu and Gln C4/C3 proton signals, whose amplitudes are greater than the 2HG 2.25-ppm signal at zero TE (by 1.16-and 1.08-fold, respectively), were extensively suppressed; as a result, the Glu and Gln signals between 2.2 and 2.3 ppm were $3% and $7%, respectively, with respect to 2HG. The GABA 2.29-ppm resonance, which also gives a larger signal (1.29-fold) than 2HG at zero TE, was markedly reduced (2.8-fold), resulting in a smaller signal (82%) than the 2HG signal. The 2HG 2.25-ppm signal yield of the sequence was 56% compared with 90 -acquisition for a localized volume, ignoring T 2 relaxation effects. For the 2HG-suppressed subecho time set, the 2HG signal was essentially null between 2.2 and 2.3 ppm, in which the GABA signal was dominant (Fig. 4b) .
We tested the 2HG-optimized and 2HG-suppressed triple-refocusing sequences in a 2HG plus Gly phantom and in an IDH-mutated glioma patient in vivo (Fig. 5) . The calculated 2HG spectra were in excellent agreement with phantom spectra for both triple-refocusing schemes. For the 2HG-optimized sequence, the calculated and phantom spectra both showed a large and narrow 2HG ) of the triple-refocusing sequence used in the study. The 2HG peak amplitude was obtained from the spectra broadened to singlet line width of 5 Hz.
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peak at 2.25 ppm, with small signals at $1.9 and $4.0 ppm. For a Gly 3.55-ppm singlet line width of 5 Hz, the 2HG 2.25-ppm signal width in the phantom spectrum was 5.5 Hz, consistent with the simulation. The experimental 2HG 2.25-ppm peak area was $73% with respect to the Gly peak area, reproducing the prepared 2HG-toGly concentration ratio (8:10), when the phantom T 2 effects were corrected (Gly T 2 ¼ 1.4 s and 2HG T 2 ¼ 0.7 s). For the 2HG-suppressed sequence, the 2HG 2.25-ppm resonance was diminished in the phantom spectrum, as predicted by the simulation. The 2HG signal manipulation by the triple-refocusing schemes was reproduced in vivo. In an IDH-mutated oligoastrocytoma patient, a large peak was observed at 2.25 ppm in the 2HG-optimized triple-refocused spectrum, but the 2HG-suppressed triple-refocused spectrum did not present a noticeable signal between 2.2 and 2.3 ppm, indicating that the large peak at 2.25 ppm was attributed to 2HG. 
2-Hydroxyglutarate Detection by Triple Refocusing
The 2HG level in the tumor was estimated to be 15.0 mM, which was the highest among the 14 tumors studied. tCho was quite elevated (4.2 mM) compared with the published normal level from similar regions ($1.5 mM) (25) . Figure 6 compares in vivo spectra from a tumor versus the contralateral region in a subject with an IDH-mutated oligodendroglioma.
2HG-optimized triple-refocusing spectra were obtained from the tumor mass in the right insula and from a normal-appearing region in the left insula. With identical voxel size (5.8 mM) and scan time (13 min) between the scans, the signal-to-noise ratio and singlet line width were similar between the spectra. The overall spectral pattern was different between the spectra due to the differences in metabolite concentrations. The spectrum from the tumor showed slight elevation of . Spectra were normalized to STEAM TE ¼ 13 ms water. The metabolite concentrations in the contralateral were estimated with reference to water at 40 M following the correction for relaxation effects using T 2 ¼ 150, 240, 290, and 180 ms for tCr, tCho, tNAA, and other metabolites, respectively (21, 22) , and T 1 values used for tumor data correction.
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tCho and tCr and marked decrease in tNAA, compared with the contralateral. A large signal was present at 2.25 ppm in the tumor spectrum. The 2HG level in the tumor was estimated to be 5.4 mM, with CRLB of 5%. The data from the contralateral voxel did not show evidence of 2HG. GABA was not reliably measurable in the tumor or in the contralateral voxel. Because the 2HG-optimized triple-refocusing sequence was designed for improving 2HG detectability, we compared its performance with a previously reported PRESS TE ¼ 97 ms method (11) in an IDH-mutated tumor with relatively low 2HG concentration (Fig. 7) . The metabolite signals were overall smaller in the triple-refocused spectrum than in the PRESS spectrum, largely due to differences in T 2 relaxation effects (TE ¼ 137 versus 97 ms). In the PRESS spectrum (Fig. 7b) , a signal was discernible at $2.25 ppm, and the signal was overlapped extensively with a much larger Glu signal at 2.35 ppm. LCModel analysis of the PRESS data resulted in a 2HG estimate of 0.6 mM (CRLB ¼ 61%), with a GABA estimate of 2.3 mM. In the triple-refocused spectrum, the Glu C4 proton resonance was drastically attenuated, giving rise to a signal at 2.25 ppm (Fig. 7a, inset) . 2HG was estimated to be 2.4 mM with a much smaller CRLB (11%). The GABA estimate was 0.9 mM, which may be slightly lower than normal similarly to moderate decreases in tNAA and Glu. Despite the larger T 2 signal loss the triple refocusing provided improved precision compared with the published long-TE PRESS method, which was largely due to line narrowing of 2HG and suppression of Glu, Gln, and GABA resonances.
In addition, we tested the 2HG-optimized MRS in a subject with a lesion in the brainstem. The patient did not undergo biopsy, thus the lesion was clinically undefined. A regular clinical MR scan (which had been done independently of the present study) showed increases in tCho and Lac and decreases in tCr and tNAA, which are commonly observed in many tumors. Given that these metabolic alterations also occur in other neurological diseases such as stroke, multiple sclerosis, and demyelination (26) , the abnormal levels of those metabolites did not provide useful clinical information. Our triple-refocusing MRS scan showed elevated 2HG, indicating the lesion was an IDH-mutated glioma. A 2HG signal at 2.25 ppm was clearly discernible without considerable interferences in the proximity (Fig. 8) . A composite signal at $4.05 ppm was decomposed into 2HG (4.02 ppm) and mI (4.06 ppm) 
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signal in the spectral fitting. The 2HG level was estimated to be 4.7 mM with CRLB of 5%. GABA was undetectable, suggesting that the low-concentration neurotransmitter in the white-matter dominant region was substantially decreased due to the presence of tumor cells. For the MRS scans in the 15 patients in this study, the mean voxel size was 7.1 6 2.5 mL, with a mean line width of the tCho singlet at 6.7 6 1.7 Hz. With an average scan time of 7.1 6 4.6 min, the tCho peak amplitude-to-noise ratio was 163 6 82, where the noise standard deviation was calculated from the spectral region between À5 and 0 ppm. 2HG was measurable in all 15 patients. The estimated 2HG levels ranged from 2.4 to 15.0 mM (mean ¼ 5.4 6 3.2 mM), with CRLBs between 2% and 11% (mean ¼ 6 6 2%). The GABA estimation was relatively less reliable. Excluding three cases with zero GABA estimates, the mean GABA level was obtained as 0.3 6 0.2 mM, with mean CRLB of 252% 6 387%. The LCModel-returned correlation coefficient between 2HG and GABA signals ranged from À0.32 to À0.08 (mean ¼ À0.18 6 0.07). The correlation coefficients of 2HG signal with respect to Glu and Gln were relatively small (i.e., ranging from À0.08 to 0.13 and from À0.08 to 0.17, respectively), which may be due to the Glu and Gln signal suppression. tCho was elevated in all the tumors studied, with a mean level at 3.7 6 2.3 mM (CRLB ¼ 1% for all). tNAA was substantially decreased (mean ¼ 2.8 6 2.2 mM). Lastly, we evaluated potential correlation between 2HG and tCho levels in our data set. Figure 9 presents the 2HG and tCho estimates from the 14 patients with biopsy-confirmed IDH1 R132H mutated gliomas (excluding a brainstem tumor). There was no evidence of significant correlation between the metabolite concentrations (P ¼ 0.28).
DISCUSSION
The current paper reports a new triple-refocusing approach for 2HG detection at 3T. Taking advantage of the high variability of J-coupled spin signals with changes of the three subecho times, the signals of 2HG, GABA, Glu, and Gln were effectively manipulated for improving the 2HG detectability in vivo. With the 2HG-optimized triple-refocusing scheme, considerable line narrowing of the 2HG 2.25-ppm multiplet was achieved with good signal yield. Moreover, the signals of Glu and Gln were suppressed extensively, giving nearly no interferences with 2HG measurement. The GABA 2.29-ppm resonance was also suppressed. Assuming that GABA is decreased in brain tumors similarly to NAA and Glu, the interference of residual GABA signals with 2HG evaluation may not be considerable in many tumors. When the GABA 2.29 ppm signal is not negligible compared with the 2HG 2.25 ppm peak, separation of 2HG from GABA may be achievable by the 2HG 4.0 ppm resonance whose signal is $40% of the 2HG 2.25 ppm signal. In addition, the triple refocusing sequence with TE ¼ 137 ms gives rise to an inverted Lac signal at 1.31 ppm, thus Lac can be easily resolved from the overlapping signals of lipids, which are increased in some tumors.
Compared with PRESS short TE (30 ms) and TE ¼ 97 ms (11) , the 2HG-optimized triple refocusing gives a smaller 2HG 2.25-ppm signal (Fig. 10) . The 2HG 2.25-ppm peak amplitude ratio between the triple refocusing, PRESS TE ¼ 97 ms, and PRESS TE ¼ 30 ms was calculated to be 72:76:100. The signal reduction at the long TEs will be extensive in vivo because of the T 2 relaxation effect. However, high signal selectivity is important for reliable measurement of 2HG. Whereas the signals of 2HG, Glu, and Gln are overlapped extensively with each other at short TE, PRESS TE ¼ 97 ms provides signal narrowing and consequently improved spectral resolution between 2HG, Glu, and Gln (Fig. 10b,c) . However, PRESS TE ¼ 97 ms does not fully differentiate the 2HG signal from the adjacent resonances, thus 2HG evaluation will be compromised when the Glu and Gln signals are much larger than the 2HG signal (as shown in Fig. 7) . The triple refocusing provides excellent suppression of these major interference signals between 2.2 and 2.3 ppm and suppression of the GABA 2.29-ppm resonance by $50% with respect to the PRESS TE ¼ 97 ms method (Fig. 10a,b) . Benefits from this signal suppression were observed in terms of CRLB and LCModel-returned correlation coefficient, which is a measure of the dependency (or interference) between metabolite signal estimates. For the 15 tumors studied, the mean 2HG CRLB was clearly smaller in triple refocusing than in PRESS TE ¼ 97 ms (6% 6 2% versus 9% 6 15%) although the mean 2HG estimate was about the same between the methods (5.4 6 3.2 versus 5.5 6 3.7 mM). The correlation coefficients of 2HG with respect to GABA, Glu, and Gln ranged from À0.32 to À0.08, À0.08 to 0.13, and À0.08 to 0.17 for triple refocusing and À0.28 to À0.62, 0.18 to 0.42, and À0.11 to 0.22 for PRESS TE ¼ 97 ms, respectively. It is noteworthy that the tCho singlet amplitude-to-noise ratio was about the same between the triple refocusing TE ¼ 137 ms and PRESS TE ¼ 97 ms (171 6 68 versus 172 6 81) largely due to difference in the tCho singlet line width between the methods (FWHM 6.7 6 1.7 versus 7.1 6 2.0 Hz, P ¼ 0.02). Among the 14 IDH-mutated tumors, triple refocusing gave all meaningful 2HG measures, whereas the long-TE PRESS failed in one case (Fig.  7) . Taken together, the 2HG-optimized triple refocusing approach may provide more reliable estimation of 2HG than the PRESS short-and long-TE methods. In the present triple-refocusing study, the carrier frequency of the non-slice selective 180 RF pulse (NS180), n c NS180 , was set to 2.5 ppm throughout the experiments. It is noteworthy that the J-coupled spin metabolite signals following the triple-refocusing sequence is affected by n c NS180 . For the 26-ms-long RF pulse used, the 180 action is equally uniform over the 2HG resonances for n c NS180 ¼ 3.5, 3.0, and 2.5 ppm. The resulting 2HG signal for the 2HG-optimized triple refocusing is quite different between these carrier frequencies, whereas the singlet intensity is identical. The 2HG 2.25-ppm signal intensity was calculated to be 81:86:100 for n c NS180 ¼ 3.5, 3.0, and 2.5 ppm, respectively, ignoring T 2 relaxation effects. The overall pattern of the 2HG signal was also influenced by the NS180 carrier frequency. The triple-refocusing scheme used for experiments in this study had an NS180 as the second 180 pulse. This triple-refocusing scheme is likely advantageous over the scheme with an NS180 as the first or third 180 pulse. A computer simulation indicated that the 2HG signal is overall smaller and broader in the scheme with an NS180 as the first 180 pulse compared with the triple-refocusing sequence of the present study. For the scheme with an NS180 as the third 180 pulse, the 2HG signals were similar as in the scheme used for experiments, but with the presence of a non-slice selective RF action at the end of the sequence, the volume localization performance may be low.
There are several pitfalls in the 2HG estimation in the present study. First, due to the use of long TE (137 ms), accurate evaluation of 2HG requires a 2HG T 2 value in tumors, which has not been reported to date. Potential 2HG T 2 variations between tumors will cause errors in 2HG estimation. Second, use of STEAM water as reference causes some errors because the frequency profiles of the slice-selective 90 and 180 RF pulses used were not identical [i.e., transition width/bandwidth ffi 10% and 12%, respectively (27) ]. The discrepancy between the STEAM and PRESS voxel shapes was ignored in this study. Given that water T 2 is quite different between tumors (21), the errors arising from the profile discrepancy may be smaller than the errors that can be introduced when triple-refocused water signal at the shortest possible TE ($70 ms) is used as reference. Lastly, metabolites were quantified with reference to water at 48 M, which was determined based on proton density images from seven tumors (data not shown) that showed the tumor water signal higher by 19% than the white-matter water concentration (40 M) (28) . Use of a constant water concentration will cause errors in metabolite quantification when the water concentration differs between tumors.
Our in vivo 2HG data from IDH1 mutated gliomas did not show significant correlation with tCho, in contrast to a prior ex vivo 1 H MRS study (29) . The tCho elevation was moderate to high in our data, with concentrations ranging from 1.5 to 11 mM. tCho is elevated in brain tumors due to increased phospholipid metabolism (30, 31) . Specifically, elevation of tCho in IDH1-mutant gliomas may be attributed to membrane synthesis of mitochondria which is increased to compensate for the use of a-ketoglutarate and NADPH for the a-ketoglutarate to 2HG conversion in the cytosol (32) . IDH wild-type and IDH2-mutated tumors may not exhibit increased mitochondrial number (32), but they show marked elevation of tCho, which may be due to rapidly proliferating tumor cells (30) . Thus, increased phospholipid metabolism may not provide definitive identification of IDH1 mutation status, as opposed to a proposal in a preclinical 31 P MRS study (31) . Further study is required to find a potential causal relationship among phospholipid metabolism, tCho increase, and 2HG production. 
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patients noninvasively has significant relevance in patient care. Diagnostic and prognostic information offered by noninvasive detection of 2HG may significantly impact treatment decision in glioma patients, especially when the tumor is located in the brain region where a biopsy is associated with a risk of permanent neurological injury (e.g., brainstem). This requires precise evaluation of 2HG. Our proposed triple-refocusing method provides a new tool for improved measurement of 2HG with good suppression of adjacent resonances, making it possible to evaluate 2HG in small tumors with low cellularity. Importantly, several therapeutic studies targeting mutated forms of IDH1 and IDH2 (33) are currently underway. Reliable measurement of 2HG may also have significant potential for drug development.
